3-year grant received from the Bill & Melinda Gates Foundation to enhance RNA production technologies Grant enables global implementation of the ...
Tanvex BioPharma, Inc. (“Tanvex”), a contract development and manufacturing organization (CDMO) for biologics and a biosimilars product...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced the launch of ...
Duality Biologics ("DualityBio") announced that, BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C907...
Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Nov...
In a compelling conversation with BioPharma BoardRoom, Venkata Indurthi, Chief Scientific Officer at Aldevron, shares insights into the inn...
Amarna Therapeutics, (“Amarna” or “the Company”), a privately held biotechnology company specializing in transformative gene therap...
Polyrizon Ltd. (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, anno...
Adragos Pharma, a global Contract Development and Manufacturing Organization (CDMO) headquartered in Munich, has announced the acquisition of Baccinex, a...
Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, just completed significant expansions in...
" Abzena, a leading CDMO/CRO, now offers GMP cell-based potency assays at its UK and US sites, enhancing its support for complex biologics and ADC programs...
" Ardena, a leading CDMO, has received full GMP approval for its advanced nanomedicine facility in Oss. This €20 million investment, featuring state...
Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlan...
Merck, a leading science and technology company, announced a € 70 million expansion of its ADC manufacturing capabilities and capacity at its Bioconju...
© 2025 Biopharma Boardroom. All Rights Reserved.
